Navigation Links
Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop

/ II Trial of VELCADE and Perifosine (KRX-0401) in Relapsed / Refractory Multiple Myeloma Patients Previously Treated with VELCADE: Preliminary Results * Lead investigator: Paul Richardson, M.D., Dana-Farber Cancer Institute * Abstract #608; Poster session: Thursday 28th June, 4:30 p.m. -- Combination of the mTOR-Inhibitor Rapamycin and Proteasome Inhibitor VELCADE is Synergistic In Vitro in Multiple Myeloma * Lead investigator: Xavier Leleu, M.D., Centre Hospitalier Regional Universitaire de Lille * Abstract #534; Poster session: Tuesday 26th June, 4:30 p.m.

About Multiple Myeloma (MM)

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and close to 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and more than 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is c
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015  Research and Benchmarking ... sixth Medical Affairs Roundtable on Thursday, ... a virtual roundtable to discuss "Medical Affairs, Role ... Best Practices, Medical Affairs Consortium provides Medical Affairs ... the key challenges they face. The consortium has ...
(Date:5/22/2015)... 2015 /CNW/ - The Taskforce representing Canada,s ... the hard work that the Minister and Health Canada have ... program recognizes the needs of the thalidomide survivors, and more ... year, tax free, with annual adjustments for inflation. ... payments of $100,000 based on the severity of their disability, ...
(Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
(Date:5/22/2015)... “It’s like learning an new language,” ... President of Clinical Operations/Education and Training at Harmony ... how care is coded and reimbursed.” , Harmony ... reimbursement, operations and compliance consulting, as well as ... a new series of day-long seminars on the ...
(Date:5/22/2015)... 2015 Coordinating care for people ... Historically providers have not been reimbursed or rewarded ... 2015, Medicare has paved the way by offering ... the launch of Oculus Health , an ... using the platform will now be able to ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 According to ... hub for drug related death, totaling almost 2,500 confirmed drug ... reported by state officials, totals 2,489 deaths stemming from legal ... out, Pennsylvania loses seven people every day to fatal overdoses ... been singled out as one of the most rife with ...
(Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
Breaking Medicine News(10 mins):Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2
... percent; real number may be as low as 4 percent, ... new, closer look at data on Caesarean section births in ... surgical deliveries is far lower than previously thought. , When ... C-sections being performed in the United States on women who ...
... conducted by University of Denver (DU) Associate Professor Rene ... undergraduate students to wash their hands more frequently after ... researchers posted messages in the bathrooms of two DU ... on you, wash your hands" or "You just peed, ...
... , ... Phoenix, AZ (Vocus) December 23, 2008 -- Adding to a ... results released in the December 23rd issue of Circulation further emphasized the ... sedentary job structures most Americans fall far short of the minimum recommended ...
... and Translational Science (CCTS) has awarded 18 grants ... grant program. The grants, which range from $2,000 ... translational science that, if successful, might lead to ... funds from a 2006 Clinical and Translational Science ...
... Mixing prescription, nonprescription meds poses dangers, researchers say , , ... 4 percent of older adults in the United States ... put them at risk for potentially dangerous interactions, a ... adults over 65 account for more than 175,000 emergency ...
... Women who did weight-bearing sports such as swimming had greater ... News) -- Doing weight-bearing exercise during adolescence may help women ... says. , Published online Dec. 22 in the British ... conclusions by looking at the teenage exercise habits of 46 ...
Cached Medicine News:Health News:Rate of Unnecessary C-Sections Far Lower Than Thought 2Health News:Rate of Unnecessary C-Sections Far Lower Than Thought 3Health News:University of Denver uses 'gross' messaging to increases handwashing, fight Norovirus 2Health News:Treadmill Desks to the Rescue: Weight Control and Activity Critical in Preventing Heart Failure 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 3Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 4Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... Standard/Conventional Blade. Stainless steel. Lamp supplied ... tradition of high quality standard incandescent ... blades have been continually refined through ... over to minimize maintenance requirements. They ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
Medicine Products: